Jun 2026 (Q2 FY26) — Aug 6, 2026
BioMarin Q2 FY26 — Strong Growth, Amicus Integration Exceeds Expectations, VOXZOGO Guidance Raised
Read the full callBioMarin (BMRN) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
BioMarin earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 990 | +19.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 11.2 | −22.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 44.8 | −81.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
18 of 22 judged targets kept · 40 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Amicus integration roadmap and growth acceleration details | share roadmap and more detail on growth acceleration | Mar 2026 | Today, we provide estimated peak revenue for Galafold of $1.4 billion and for Pombiliti and Opfolda of $1.2 billion. | Achieved |
| BMN 333 detailed data presentation | presented at a scientific congress | Dec 2024 | Ghosted | |
| VOXZOGO revenue | $975 million to $1.025 billion | Dec 2025 | we feel comfortable increasing VOXZOGO revenue guidance for the year for over $1 billion. | Revised Up |
4 of BIOMARIN PHARMACEUTICAL INC's 62 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 59 more targets are in the full ledger.
Claimed
- Total revenue grew 20% year-over-year to nearly $1 billion, driven by a diversified portfolio.
- VOXZOGO revenue guidance was increased, putting it on a path to become BioMarin's first $1 billion product.
- Amicus integration is outperforming, with estimated peak revenues of $1.4 billion for Galafold and $1.2 billion for Pombiliti and Opfolda.
- Significant cost synergies of approximately $220 million annual run rate are expected by 2028 from the Amicus acquisition.
- Submitted sNDA for VOXZOGO to treat hypochondroplasia in a record 79 days from database lock.
Qualified
- Approximately 10% of U.S. VOXZOGO patients switched to a competitor product since its February approval, representing less than 100 patients.
- Interest expense increased year-over-year due to acquisition debt financing, estimated at approximately $200 million annually.
- Interest income decreased due to liquidated investments to fund the acquisition.
Price
$56.05 +1.65% · +$0.91
Performance +6.8% 1Y
1Y: $52.47 on 14 Oct 2025 → $56.05. High $70.24 (12 Aug 2026), low $49.67 (18 May 2026).
- Previous close
- $55.14
- 52-week range
- $49.67 – $70.24
- One year
- +5.58%
Overview
- Symbol
- BMRN
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
18 of 22 judged targets kept · 40 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Amicus integration roadmap and growth acceleration details | share roadmap and more detail on growth acceleration | Mar 2026 | Today, we provide estimated peak revenue for Galafold of $1.4 billion and for Pombiliti and Opfolda of $1.2 billion. | Achieved |
| BMN 333 detailed data presentation | presented at a scientific congress | Dec 2024 | Ghosted | |
| VOXZOGO revenue | $975 million to $1.025 billion | Dec 2025 | we feel comfortable increasing VOXZOGO revenue guidance for the year for over $1 billion. | Revised Up |
Claimed
- Total revenue grew 20% year-over-year to nearly $1 billion, driven by a diversified portfolio.
- VOXZOGO revenue guidance was increased, putting it on a path to become BioMarin's first $1 billion product.
- Amicus integration is outperforming, with estimated peak revenues of $1.4 billion for Galafold and $1.2 billion for Pombiliti and Opfolda.
- Significant cost synergies of approximately $220 million annual run rate are expected by 2028 from the Amicus acquisition.
- Submitted sNDA for VOXZOGO to treat hypochondroplasia in a record 79 days from database lock.
Qualified
- Approximately 10% of U.S. VOXZOGO patients switched to a competitor product since its February approval, representing less than 100 patients.
- Interest expense increased year-over-year due to acquisition debt financing, estimated at approximately $200 million annually.
- Interest income decreased due to liquidated investments to fund the acquisition.
The full ledger
Open BIOMARIN PHARMACEUTICAL INC’s full ledger
A free account opens 5 company ledgers a month. All 62 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 4, 2026
BioMarin Q1 FY26 — Amicus Acquisition Closes, Raises FY26 Revenue Guidance
Read the full callEvery analysed call
BioMarin earnings calls (BMRN)
Financials
What the filings say
Net profit, year on year: −81% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 746 | 747 | 745 | 825 | 776 | 875 | 766 | 990 |
| Expenses | 632 | 586 | 521 | 549 | 823 | 919 | 637 | 879 |
| Operating profit | 114 | 161 | 224 | 277 | -47 | -45 | 130 | 111 |
| Operating margin | 15.3% | 21.6% | 30.1% | 33.5% | −6.0% | −5.1% | 16.9% | 11.2% |
| Interest | 3 | 3 | 3 | 3 | 3 | 3 | 15 | 63 |
| Profit before tax | 134 | 170 | 238 | 298 | -26 | -27 | 141 | 61 |
| Tax rate | 21.1% | 26.4% | 22.0% | 19.3% | −16.8% | −71.5% | 25.3% | 27.1% |
| Net profit | 106 | 125 | 186 | 241 | -31 | -47 | 106 | 45 |
| EPS ($ per share) | 0.56 | — | 0.97 | 1.25 | -0.16 | — | 0.55 | 0.23 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -1,694 | -1,721 | -862 | -931 | -789 | -622 | -195 | 154 |
| Total liabilities | 1,459 | 1,568 | 1,742 | 1,739 | 1,772 | 1,890 | 1,331 | 1,507 |
| Fixed assets | 949 | 1,011 | 1,032 | 1,035 | 1,073 | 1,066 | 1,043 | 953 |
| Total assets | 4,427 | 4,690 | 5,848 | 6,005 | 6,375 | 6,842 | 6,989 | 7,594 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 20 | 48 | 85 | 305 | 176 | 159 | 573 | 828 |
| Cash from investing | 264 | -31 | -54 | -366 | -20 | -111 | 136 | -414 |
| Cash from financing | -388 | -75 | 181 | -0 | -19 | -19 | -526 | -42 |
| Net cash flow | -104 | -57 | 212 | -62 | 137 | 31 | 188 | 369 |
| Capital expenditure | -145 | -145 | -114 | -96 | -121 | -97 | -85 | -103 |
| Free cash flow | -124 | -97 | -29 | 209 | 55 | 63 | 487 | 725 |
BMRN revenue by segment
| Segment | Q2 FY2024 | Q3 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Reportable | — | — | 100% | 100% | 100% | 100% | 100% | 100% | +19.9% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q2 FY2026 · share of revenue
- US 37%
- Europe 30% ↑ 4 pt
- Rest Of World 17%
- Latin America 11% ↓ 5 pt
As BMRN cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
45 filings between Dec 1, 2025 and Sep 30, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$4.32M
5 sales by 3 insiders
Compensation
not trading decisions- 27
- Award — granted as compensation
- 13
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Davis George Eric | — | $2.76M | Sep 2, 2026 |
| Guyer Charles Greg | — | $996.7K | Mar 11, 2026 |
| Friberg Gregory R | — | $558.6K | May 7, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 30, 2026 | Friberg Gregory R EVP, Chief R&D Officer | Tax withheld | 4,086 | $245.2K |
| Sep 10, 2026 | Plenge Robert M Director | Award | 6,140 | $0 |
| Sep 2, 2026 | Davis George Eric EVP, Chief Legal Officer | Sale | 17,557 | $1.16M |
| Jun 2, 2026 | HOMBACH ROBERT J. Director | Award | 7,490 | $0 |
| Jun 2, 2026 | Ho Maykin Director | Award | 7,490 | $0 |
| Jun 2, 2026 | Walbert Timothy P Director | Award | 7,490 | $0 |
| Jun 2, 2026 | Countouriotis Athena Director | Award | 7,490 | $0 |
| Jun 2, 2026 | Dere Willard H Director | Award | 7,490 | $0 |
| Jun 2, 2026 | ANDERSON ELIZABETH M Director | Award | 7,490 | $0 |
| Jun 2, 2026 | Enyedy Mark J Director | Award | 7,490 | $0 |
| Jun 2, 2026 | Bodem Barbara W. Director | Award | 7,490 | $0 |
| Jun 2, 2026 | CLARK IAN T Director | Award | 7,490 | $0 |
| May 20, 2026 | Hubbard Cristin EVP, Chief Commercial Officer | Tax withheld | 2,318 | $116.4K |
| May 7, 2026 | Friberg Gregory R EVP, Chief R&D Officer | Sale | 3,281 | $176.7K |
| Mar 18, 2026 | Davis George Eric EVP, Chief Legal Officer | Tax withheld | 1,273 | $71.4K |
| Mar 17, 2026 | Mueller Brian EVP, Chief Financial Officer | Tax withheld | 2,117 | $118.7K |
| Mar 17, 2026 | Guyer Charles Greg EVP, Chief Technical Officer | Tax withheld | 1,693 | $94.9K |
| Mar 17, 2026 | Hardy Alexander Chief Executive Officer | Tax withheld | 4,252 | $238.3K |
| Mar 17, 2026 | Friberg Gregory R EVP, Chief R&D Officer | Tax withheld | 1,629 | $91.3K |
| Mar 17, 2026 | Hubbard Cristin EVP, Chief Commercial Officer | Tax withheld | 1,245 | $69.8K |
| Mar 16, 2026 | Hubbard Cristin EVP, Chief Commercial Officer | Award | 15,410 | $0 |
| Mar 16, 2026 | Friberg Gregory R EVP, Chief R&D Officer | Award | 19,150 | $0 |
| Mar 16, 2026 | Mueller Brian EVP, Chief Financial Officer | Award | 18,740 | $0 |
| Mar 16, 2026 | Hardy Alexander Chief Executive Officer | Award | 62,440 | $0 |
| Mar 16, 2026 | Davis George Eric EVP, Chief Legal Officer | Award | 14,570 | $0 |
| Mar 16, 2026 | Davis George Eric EVP, Chief Legal Officer | Tax withheld | 7,177 | $419.9K |
| Mar 16, 2026 | Guyer Charles Greg EVP, Chief Technical Officer | Award | 14,990 | $0 |
| Mar 13, 2026 | Mueller Brian EVP, Chief Financial Officer | Tax withheld | 9,945 | $581.9K |
| Mar 13, 2026 | Guyer Charles Greg EVP, Chief Technical Officer | Tax withheld | 9,109 | $533.0K |
| Mar 13, 2026 | Hardy Alexander Chief Executive Officer | Tax withheld | 2,941 | $172.1K |
| Mar 11, 2026 | Guyer Charles Greg EVP, Chief Technical Officer | Sale | 16,486 | $996.7K |
| Feb 26, 2026 | Friberg Gregory R EVP, Chief R&D Officer | Sale | 6,326 | $381.9K |
| Feb 26, 2026 | Davis George Eric EVP, Chief Legal Officer | Sale | 26,061 | $1.60M |
| Feb 25, 2026 | Davis George Eric EVP, Chief Legal Officer | Award | 2,372 | $0 |
| Feb 25, 2026 | Guyer Charles Greg EVP, Chief Technical Officer | Award | 6,176 | $0 |
| Feb 25, 2026 | Guyer Charles Greg EVP, Chief Technical Officer | Award | 6,675 | $0 |
| Feb 25, 2026 | Guyer Charles Greg EVP, Chief Technical Officer | Award | 2,371 | $0 |
| Feb 25, 2026 | Mueller Brian EVP, Chief Financial Officer | Award | 7,230 | $0 |
| Feb 25, 2026 | Davis George Eric EVP, Chief Legal Officer | Award | 6,177 | $0 |
| Feb 25, 2026 | Davis George Eric EVP, Chief Legal Officer | Award | 6,675 | $0 |
| Feb 25, 2026 | Mueller Brian EVP, Chief Financial Officer | Award | 6,683 | $0 |
| Feb 25, 2026 | Mueller Brian EVP, Chief Financial Officer | Award | 2,569 | $0 |
| Jan 20, 2026 | Ramchandani Rashmi Virendra VP, Chief Accounting Officer | Award | 7,070 | $0 |
| Jan 20, 2026 | Ramchandani Rashmi Virendra VP, Chief Accounting Officer | Award | 18,540 | $0 |
| Dec 1, 2025 | Hardy Alexander Chief Executive Officer | Tax withheld | 16,570 | $911.8K |
| Sep 30, 2025 | Friberg Gregory R EVP, Chief R&D Officer | Tax withheld | 3,304 | $178.9K |
| Aug 1, 2025 | CLARK IAN T Director | Award | 7,000 | $0 |
| May 20, 2025 | Dere Willard H Director | Award | 6,650 | $0 |
| May 20, 2025 | ANDERSON ELIZABETH M Director | Award | 6,650 | $0 |
| May 20, 2025 | Bodem Barbara W. Director | Award | 6,650 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for BIOMARIN PHARMACEUTICAL INC
Free account. Everything above stays public.
Write why you follow BIOMARIN PHARMACEUTICAL INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading